Payment overview · 2025
General Payments
$217.81
10 reported records · 7 companies
Healthcare provider profile · identity verified
Michael C Harper, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SELLERSBURG, IN · NPI 1487615415
Verified facts
What the public records show
CMS Open Payments records show Michael C Harper, MD received $217.81 in general payments during 2025 across 10 reported records.
Exact Sciences Corporation accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.50 | 21.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $42.93 | 19.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $42.66 | 19.6% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $29.20 | 13.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.68 | 9.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$18.21 | 8.4% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $16.63 | 7.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $217.81 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $47.50 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.66 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.66 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.90 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $18.21 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $16.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
75 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1011 | 279 |
| Amlodipine Besylate | Amlodipine Besylate | 632 | 174 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 522 | 152 |
| Lisinopril | Lisinopril | 434 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 429 | 119 |
| Metoprolol Succinate | Metoprolol Succinate | 378 | 120 |
| Pantoprazole Sodium | Pantoprazole Sodium | 343 | 112 |
| Omeprazole | Omeprazole | 288 | 86 |
| Losartan Potassium | Losartan Potassium | 276 | 79 |
| Metformin Hcl | Metformin Hcl | 251 | 68 |
| Alprazolam | Alprazolam | 243 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 232 | 69 |
| Carvedilol | Carvedilol | 224 | 60 |
| Gabapentin | Gabapentin | 218 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 67 |
| Meloxicam | Meloxicam | 211 | 75 |
| Furosemide | Furosemide | 204 | 70 |
| Ezetimibe | Ezetimibe | 189 | 63 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 179 | 46 |
| Simvastatin | Simvastatin | 178 | 51 |
| Eliquis | Apixaban | 175 | 46 |
| Alendronate Sodium | Alendronate Sodium | 168 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 160 | 48 |
| Clonazepam | Clonazepam | 139 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 139 | 39 |
| Glimepiride | Glimepiride | 135 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 39 |
| Montelukast Sodium | Montelukast Sodium | 134 | 37 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 131 | 40 |
| Potassium Chloride | Potassium Chloride | 130 | 40 |
| Sertraline Hcl | Sertraline Hcl | 129 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 43 |
| Bupropion Xl | Bupropion Hcl | 118 | 30 |
| Chlorthalidone | Chlorthalidone | 106 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 104 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 103 | 20 |
| Trazodone Hcl | Trazodone Hcl | 102 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 96 | 29 |
| Allopurinol | Allopurinol | 91 | 28 |
| Atenolol | Atenolol | 91 | 26 |
| Metformin Hcl Er | Metformin Hcl | 91 | 30 |
| Warfarin Sodium | Warfarin Sodium | 83 | 14 |
| Ozempic | Semaglutide | 82 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 24 |
| Synthroid | Levothyroxine Sodium | 75 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 66 | 21 |
| Doxazosin Mesylate | Doxazosin Mesylate | 64 | 19 |
| Celecoxib | Celecoxib | 61 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 61 | 17 |
| Finasteride | Finasteride | 59 | 18 |
| Prednisone | Prednisone | 59 | 41 |
| Tramadol Hcl | Tramadol Hcl | 58 | 16 |
| Januvia | Sitagliptin Phosphate | 54 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 12 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 53 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 16 |
| Donepezil Hcl | Donepezil Hcl | 52 | 16 |
| Repatha Sureclick | Evolocumab | 51 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 50 | 16 |
| Testosterone Cypionate | Testosterone Cypionate | 47 | suppressed |
| Baclofen | Baclofen | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 44 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 13 |
| Estradiol | Estradiol | 41 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 13 |
| Diazepam | Diazepam | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | 13 |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Entresto | Sacubitril/Valsartan | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 12 |
| Famotidine | Famotidine | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 29 | 11 |
| Verapamil Er | Verapamil Hcl | 29 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 26 |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 25 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Praluent Pen | Alirocumab | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 12 |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 19 | 19 |
| Calcitriol | Calcitriol | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 19 |
| Amoxicillin | Amoxicillin | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 15 |
| Invokana | Canagliflozin | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Cilostazol | Cilostazol | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Rybelsus | Semaglutide | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $217.81 · 10 records | Exact Sciences Corporation | Cologuard Collection Kit, EVENITY, Flucelvax, KISUNLA, MINIMED 780G, MOUNJARO, QULIPTA, UBRELVY, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error